Cipla Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Umang Vohra

Chief Executive Officer (CEO)

₹222.1m

Compensación total

Porcentaje del salario del CEO	36.7%
Permanencia del CEO	8yrs
Participación del CEO	0.04%
Permanencia media de la dirección	5yrs
Promedio de permanencia en la Junta Directiva	5.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Umang Vohra en comparación con los beneficios de Cipla?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	₹43b
Mar 31 2024	₹222m	₹82m	₹41b
Dec 31 2023	n/a	n/a	₹37b
Sep 30 2023	n/a	n/a	₹35b
Jun 30 2023	n/a	n/a	₹31b
Mar 31 2023	₹175m	₹80m	₹28b
Dec 31 2022	n/a	n/a	₹26b
Sep 30 2022	n/a	n/a	₹26b
Jun 30 2022	n/a	n/a	₹25b
Mar 31 2022	₹229m	₹75m	₹25b
Dec 31 2021	n/a	n/a	₹26b
Sep 30 2021	n/a	n/a	₹26b
Jun 30 2021	n/a	n/a	₹25b
Mar 31 2021	₹181m	₹20m	₹24b
Dec 31 2020	n/a	n/a	₹22b
Sep 30 2020	n/a	n/a	₹18b
Jun 30 2020	n/a	n/a	₹16b
Mar 31 2020	₹136m	₹20m	₹15b
Dec 31 2019	n/a	n/a	₹17b
Sep 30 2019	n/a	n/a	₹16b
Jun 30 2019	n/a	n/a	₹16b
Mar 31 2019	₹150m	₹20m	₹15b
Dec 31 2018	n/a	n/a	₹13b
Sep 30 2018	n/a	n/a	₹14b
Jun 30 2018	n/a	n/a	₹15b
Mar 31 2018	₹189m	₹20m	₹14b

Compensación vs. Mercado: La compensación total de Umang($USD2.10M) está por debajo de la media de empresas de tamaño similar en el mercado Luxembourg ($USD4.52M).

Compensación vs. Ingresos: La compensación de Umang ha aumentado más de un 20% en el último año.

CEO

Umang Vohra (53 yo)

8yrs

Permanencia

₹222,100,000

Compensación

Mr. Umang Vohra, B.E., M.B.A. has been Global Chief Executive Officer, Managing Director and Executive Director of Cipla Limited since September 1, 2016. As Cipla’s MD & GCEO, Mr. Vohra’s priorities have b...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Umang Vohra	MD, Global CEO & Executive Director	8yrs	₹222.10m	0.040% ₹ 6.3m
Raju Mistry	President & Global Chief People Officer	5.4yrs	sin datos	sin datos
Pradeep Bhadauria	President & Global Chief Scientific Officer	4.5yrs	sin datos	sin datos
Ashish Adukia	Global Chief Financial Officer	2.1yrs	sin datos	sin datos
Dinesh Jain	Senior VP & Head of Corporate Finance	no data	sin datos	sin datos
Sneha Hiranandani	Chief Information Officer	less than a year	sin datos	sin datos
Naveen Bansal	Head of Investor Relations	no data	sin datos	sin datos
Rajendra Chopra	Compliance Officer & Company Secretary	7.6yrs	₹15.30m	sin datos
Heena Kanal	Senior Vice-President of Corporate Communications	no data	sin datos	sin datos
Jaideep Gogtay	Global Chief Medical Officer	less than a year	sin datos	sin datos
Anurag Mishra	Head of Cipla Foundation	no data	sin datos	sin datos
Kiran Pai	Head of Digital Marketing	7.7yrs	sin datos	sin datos

5.0yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CIPLA se considera experimentado (4.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Umang Vohra	MD, Global CEO & Executive Director	8yrs	₹222.10m	0.040% ₹ 6.3m
Yusuf Hamied	Non-Executive Chairman	52.2yrs	₹26.10m	18.64% ₹ 2.9b
Mustafa Hamied	Non-Executive Vice-Chairman	47.1yrs	₹26.40m	3.45% ₹ 540.1m
Punita Lal	Independent Non-Executive Director	9.8yrs	₹11.00m	sin datos
Adil Zainulbhai	Lead Independent Non-Executive Director	10.2yrs	₹10.10m	sin datos
Robert Stewart	Independent Director	3.3yrs	₹14.60m	sin datos
S. Radhakrishnan	Non-Executive Non-Independent Director	13.8yrs	₹27.60m	0.023% ₹ 3.5m
Sharmila Paranjpe	Independent Director	less than a year	sin datos	sin datos
Mandar Vaidya	Independent Director	2.2yrs	₹9.30m	sin datos
Prathivadibhayankara Ramesh	Independent Director	3.2yrs	₹10.00m	sin datos
Balram Bhargava	Independent Director	less than a year	sin datos	sin datos
Abhijit Joshi	Additional Non-Executive Director	no data	sin datos	sin datos

5.7yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: La junta directiva de CIPLA se considera experimentada (9.3 años de antigüedad promedio).

Cipla Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Cipla Limited Announces Resignation of M K Hamied as Vice Chairman and Non-Executive Director, Effective October 29, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan, Non-Executive Director

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Cipla Limited, Annual General Meeting, Aug 20, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Recent updates

Cipla Limited Announces Resignation of M K Hamied as Vice Chairman and Non-Executive Director, Effective October 29, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan, Non-Executive Director

Cipla Limited to Report Q1, 2025 Results on Jul 26, 2024

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Cipla Limited Approves the Appointment of Dr. Balram Bhargava as an Independent Director

Promoter Group Entities Reportedly Likely to Sell 2.5% Stake in Cipla worth INR 26.37 Billion via Block Deals

Cipla Limited, Annual General Meeting, Aug 20, 2024

Cipla Limited Announces Retirement of S. Radhakrishnan as Non-Executive Director

Cipla Limited to Report Q4, 2024 Results on May 10, 2024

Cipla Limited Appoints Rajeev Kumar Sinha as Senior Management Personnel and Global Chief Manufacturing Officer, Effective April 1, 2024

Cipla Limited Appoints Venkata Sai Mungara as Senior Management Personnel and Global Head - Supply Chain, Effective from 1 April 2024

Cipla Limited Announces Resignation of Ms. Samina Hamied as Executive Vice Chairperson

Torrent Pharmaceuticals Reportedly Bid to Acquire the Stake of Cipla Stalled over Valuation Differences

Torrent Pharma Calls the Reports of Cipla Acquisition as Speculative

Family Rift Clouds $7 Billion Sale of Cipla

Cipla Limited to Report Q2, 2024 Results on Oct 27, 2023

Blackstone Reportedly Withdraws Plan to Acquire Founders' Stake in Cipla

Torrent Pharma Reportedly in Advance Talks with CVC Capital to Buyout Cipla Promoters

Cipla's Founding Family's Stake Sale Reportedly in Jeopardy over $13 Billion Valuation Target

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Torrent Pharmaceutical Leads in the Race to Acquire Cipla

Torrent Reportedly in Top Gear to Close Out Cipla Buyout, in Talks with PES, Banks for Funds

Torrent Reportedly Joins Fray for Hamied Family Stake in Cipla

Blackstone Reportedly to Submit Bid for over 33% Stake in Cipla

Cipla Promoters Reportedly Mull Stake Sale to Top PE Firms Blackstone, Baring Asia

Cipla Limited Announces Change in Management

Cipla Limited, Annual General Meeting, Aug 10, 2023

Cipla Limited to Report Q1, 2024 Results on Jul 26, 2023

Shibam Group Holding Limited entered into a binding term sheet to acquire additional 51% stake in Saba Investment Ltd from Cipla Limited (NSEI:CIPLA) for $6.5 million.

Cipla Limited Announces Resignation of Peter Mugyenyi as Independent Director, Effective May 13, 2023

Cipla Limited Announces the Launch of Cippoint

Cipla Limited to Report Q3, 2023 Results on Jan 25, 2023

Cipla Limited and Cipla Usa Inc. Announces the Launch of Leuprolide Acetate Injection Depot 22.5Mg

Cipla Limited to Report Q2, 2023 Results on Nov 04, 2022

Cipla Limited Receives the Establishment Inspection Report Indicating Closure of the Inspection

Cipla Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Cipla Limited (NSEI:CIPLA) agreed to acquire additional 13.10% stake in Jiangsu Acebright Pharmaceutical Co. Limited for USD 16.40 million.

Cipla Limited Announces Executive Changes

Cipla Limited, Annual General Meeting, Aug 26, 2022

Cipla Limited Recommends Final Dividend for Fiscal Year 2021-22

Cipla Limited to Report Q1, 2023 Results on Jul 29, 2022

Cipla Limited Notifies That the United States Food and Drug Administration Conducted A Pre Approval Inspection

Cipla Limited (NSEI:CIPLA) agreed to acquire unknown stake in GoApptiv Private Limited.

Cipla Limited (NSEI:CIPLA) entered into a definitive agreement to acquire an unknown minority stake in Achira Labs Pvt. Ltd

The South African Health Products Regulatory Authority Approves Sweet-Tasting, Heat-Stable, 4-In-1 Fixed-Dose Combination of Four Antiretroviral Treatments Developed by Cipla and DNDi

Cipla Limited Recommends Dividend for the Year 2021-22

Cipla Limited Announces Commercialisation of `RT-Direct' multiplex COVID-19 RT PCR Test kit in India

Cipla Limited to Report Q4, 2022 Results on May 10, 2022

Cipla Limited Announces Resignation of Kedar Upadhye from the Position of Global Chief Financial Officer

Cipla Limited and Cipla USA, Inc. Receive Final Approval for Lanreotide Injection

Cipla Limited (NSEI:CIPLA) entered into an agreement to acquire 33% stake in Clean Max Auriga Power LLP for INR 60 million.

Cipla Receives Final Approval for Generic Version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)

Cipla Receives Final Approval for Generic Version of Sunovion Pharmaceuticals, Inc.'S Brovana® (Arformoterol Tartrate Inhalation Solution 15 Mcg/ 2Ml)

Roche India and Cipla Limited Announces First Batch of the Antibody Cocktail

Cipla Limited Announces Commercialization of Polymerase Chain Reaction (RT-PCR) Test Kit `ViraGen' for COVID-19 in India, in Partnership with Ubio Biotechnology Systems Pvt. Ltd

Cipla Limited Recommends Dividend for the Year 2020-21

Cipla Limited's Subsidiary, Cipla Gulf Fz Lcc Expands Its Partnership with Alvotech for the Marketing and Distribution of Four Biosimilar Medicines in Australia and New Zealand

Cipla Limited Announces Partnership with the Premier Medical Corporation Private Limited for Commercialisation of the Rapid Antigen Test Kits for COVID-19 in India

Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID (Lenalidomide) with Cipla

Cipla Limited Launches Covi-G for COVID-19 Rapid Antibody Detection

Cipla Limited Receives Final Approval for Generic Version of Biogen Idec Inc.'S Tecfidera® (Dimethyl Fumarate Dr Capsules 120Mg, 240Mg and 120Mg/240Mg Starter Pack)

Cipla Limited Receives Final Approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Dimethyl Fumarate DR Capsules Starter Pak

Cipla Limited Launches Generic Version of Broad-Spectrum Anti-Viral Drug Remdesivir (Branded Cipremi), to Be Used on Critically Ill Covid Patients in the Hospitals

Cipla Limited to Report Q3, 2021 Results on Feb 05, 2021

Cipla Limited to Report Q1, 2021 Results on Aug 07, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación